Author Archives: Anne De Groot
Tregitope Goes to Granada (Autoimmunity 2012)
Even though there are as many kinds of Tregs as there are types of tapas in Granada, there is only one Tregitope. The copas are flowing, and the Tregitope discovery (OK, make that SEVERAL Tregitopes) is being presented to the >3,000 participants at Autoimmunity 2012. The excitement is palpable . . . Continue reading
Tregitope Wins Big SBIR Program
Providence-based biotech EpiVax, Inc. was awarded a new NIH SBIR Phase II grant totaling $1.5M in funding from the National Institutes of Health’s (NIH) NIDDK to explore formulation, dose, route and delivery vehicle for Tregitope through the NIH Small Business Innovation Research (SBIR) program. EpiVax anticipates receiving an additional SBIR award of approximately $775,000 within the next few months, bringing the total to over $2.25 million dollars for the first half of 2012. Continue reading
Srini Kaveri to discuss IVIG and Tregitope MOA at 4th Tregitope Update
The 4th Annual Tregitope update will be held in Baltimore Maryland on April 20th, 2012 (Click here for more information). Dr. Srini Kaveri of the Centre de Recherche des Cordeliers (INSERM) in Paris will provide an update on the mechanism … Continue reading
Save the Date – 6th Vaccine Renaissance, Providence Rhode Island
EpiVax is a proud sponsor of the 6th Annual Vaccine Renaissance Conference scheduled for October 15-17, 2012 in Providence, Rhode Island. Continue reading
Updated list of Immunogenicity and Tregitope Talks 2012
Where will we be in Spring 2012? Click here to hear about our latest research and cutting edge approaches to immunogenicity solutions. . . Continue reading
Resilience and focus in Japan
Here in Tokyo, where we just participated in the “Westin Immunogenicity Seminar”, we are finding impressive resilience and focus on the future. The twin disasters of tsunami and earthquake appear to be in the past, and signs that say “Japan, rising again” greet travelers, as do signs saying “Thank you”, to the countries and corporations who contributed to the recovery from the events of March 2010. Resilience and focus are virtues worth emulating, whether in life or in biotech. Another virtue worth emulating in life and biotechnology is honesty. That should be the backbone of every relationship, whether corporate or human. Continue reading
Westin Immunogenicity Seminar March 16th
The Westin Seminar is back! Join us in Tokyo on March 16th to discuss immunogenicity risk and mitigation. Continue reading
Chocolate, flowers and balmy February weather
Things we like . . . balmy February weather, really good chocolate on Valentine’s Day (I mean REALLY good), fresh flowers every day of the week, and this article by Sirsky, Diaz-Mitoma, Golshani, Kumar and Azi . . . Continue reading
Put your mind (and hands) to work
I am always thrilled to meet people who are challenging paradigms. At a meeting last week, I heard about using ADCC to kill tumors, and learned that clinicians are now using a cocktail of monoclonals, depending on the patient’s cancer gene profile. We’re only a step away . . . Continue reading
Happy New Year! Tregitope World Tour 2012
It’s a New Year (2012) and our resolution is to keep you better informed. Here’s a list of our upcoming conferences. . . . Continue reading
